Cargando…
The post hoc analysis comparing the severity grades of chemoradiotherapy-induced oral mucositis scored between the central and local assessors in a multicenter, randomized controlled trial of rebamipide for head and neck cancer
BACKGROUND: In the treatment of head and neck cancer, severity of chemoradiotherapy-induced oral mucositis has been recognized as one of the key factors affecting the outcomes of the anticancer therapies. Therefore, the development of treatments mitigating oral mucositis would be of clinical signifi...
Autores principales: | Ueno, Takao, Zenda, Sadamoto, Konishi, Tetsuhito, Yurikusa, Takashi, Shibasaki, Yoshiyuki, Nagamoto, Hisashi, Fujii, Masato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6399175/ https://www.ncbi.nlm.nih.gov/pubmed/30426268 http://dx.doi.org/10.1007/s10147-018-1355-7 |
Ejemplares similares
-
J‐SUPPORT research policy for oral mucositis associated with cancer treatment
por: Yokota, Tomoya, et al.
Publicado: (2022) -
The effectiveness of rebamipide mouthwash therapy for radiotherapy and chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a systematic review and meta-analysis
por: Akagi, Shinsuke, et al.
Publicado: (2019) -
Efficacy and safety of rebamipide liquid for chemoradiotherapy-induced oral mucositis in patients with head and neck cancer: a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II study
por: Yokota, T., et al.
Publicado: (2017) -
The Efficacy of 2% Topical Rebamipide on Conjunctival Squamous Metaplasia and Goblet Cell Density in Dry Eye Disease
por: Simsek, Cem, et al.
Publicado: (2019) -
Preventive Efficacy and Safety of Rebamipide in Nonsteroidal Anti-Inflammatory Drug-Induced Mucosal Toxicity
por: Kim, Jeong Ho, et al.
Publicado: (2014)